(BMEA) Biomea Fusion - Ratings and Ratios
Covalent,BTK,Inhibitors,Kinase,Diabetes
BMEA EPS (Earnings per Share)
BMEA Revenue
Description: BMEA Biomea Fusion
Biomea Fusion Inc (NASDAQ:BMEA) is a biotechnology company listed on the NASDAQ exchange, operating in the biotechnology sub-industry. The companys stock performance has been under scrutiny, with its current price hovering around $1.72. Given the significant drop from its 52-week high of $12.41, its essential to examine the underlying drivers.
The companys market capitalization stands at $102.95M USD, indicating a relatively small-cap stock with potential for volatility. The absence of a price-to-earnings ratio (P/E) and forward P/E suggests that the company is currently unprofitable, which is not uncommon in the biotechnology sector where companies often invest heavily in research and development. The return on equity (RoE) of -243.95% further emphasizes the companys current unprofitable state.
To better understand the companys prospects, key performance indicators (KPIs) such as cash burn rate, research and development expenses, and pipeline progress become crucial. Investors should focus on the companys ability to advance its clinical trials, achieve regulatory milestones, and ultimately drive towards profitability. The quarterly tax provision data may indicate the companys current financial standing and potential tax liabilities or benefits.
Economic drivers for BMEA include the overall performance of the biotechnology sector, regulatory environment, and the companys ability to attract investment. The negative beta of -0.160 suggests that the stock tends to move in the opposite direction of the broader market, potentially offering a diversification benefit. However, this also warrants a closer examination of the companys specific risks and challenges.
To make an informed investment decision, its essential to analyze the companys cash flow statements, income statements, and balance sheets to gauge its financial health and potential for future growth. Additionally, monitoring news and announcements related to the companys clinical trials, product approvals, and strategic partnerships can provide valuable insights into its prospects.
BMEA Stock Overview
| Market Cap in USD | 116m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2021-04-16 |
BMEA Stock Ratings
| Growth Rating | -80.0% |
| Fundamental | 43.4% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -79.6% |
| Analyst Rating | 4.22 of 5 |
BMEA Dividends
Currently no dividends paidBMEA Growth Ratios
| Growth Correlation 3m | -9.3% |
| Growth Correlation 12m | -89.6% |
| Growth Correlation 5y | -44.7% |
| CAGR 5y | -45.35% |
| CAGR/Max DD 3y | -0.47 |
| CAGR/Mean DD 3y | -0.63 |
| Sharpe Ratio 12m | -0.79 |
| Alpha | -91.88 |
| Beta | 0.769 |
| Volatility | 86.85% |
| Current Volume | 527.6k |
| Average Volume 20d | 485.5k |
| Stop Loss | 1.7 (-11.9%) |
| Signal | -0.38 |
Piotroski VR‑10 (Strict, 0-10) 0.5
| Net Income (-112.1m TTM) > 0 and > 6% of Revenue (6% = 73.2k TTM) |
| FCFTA -1.64 (>2.0%) and ΔFCFTA -90.95pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 3860 % (prev 1484 %; Δ 2377 pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -1.37 (>3.0%) and CFO -100.1m > Net Income -112.1m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 3.68 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (40.6m) change vs 12m ago 12.73% (target <= -2.0% for YES) |
| Gross Margin 26.23% (prev 50.18%; Δ -23.95pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 1.17% (prev 4.51%; Δ -3.35pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| error: Interest Coverage Ratio cannot be calculated (needs EBITDA TTM and Interest Expense TTM) |
Altman Z'' -32.67
| (A) 0.64 = (Total Current Assets 64.7m - Total Current Liabilities 17.6m) / Total Assets 73.2m |
| (B) -5.98 = Retained Earnings (Balance) -437.3m / Total Assets 73.2m |
| warn (B) unusual magnitude: -5.98 — check mapping/units |
| (C) -1.09 = EBIT TTM -114.6m / Avg Total Assets 104.7m |
| (D) -9.58 = Book Value of Equity -437.2m / Total Liabilities 45.7m |
| Total Rating: -32.67 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 43.37
| 1. Piotroski 0.50pt = -4.50 |
| 2. FCF Yield data missing |
| 3. FCF Margin data missing |
| 4. Debt/Equity 1.05 = 1.98 |
| 5. Debt/Ebitda -0.26 = -2.50 |
| 7. RoE -244.0% = -2.50 |
| 8. Rev. Trend 7.78% = 0.39 |
| 9. Rev. CAGR 0.0% = 0.0 |
| 10. EPS Trend 20.17% = 0.50 |
| 11. EPS CAGR 0.0% = 0.0 |
What is the price of BMEA shares?
Over the past week, the price has changed by +6.63%, over one month by +14.20%, over three months by -26.62% and over the past year by -75.81%.
Is Biomea Fusion a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of BMEA is around 1.26 USD . This means that BMEA is currently overvalued and has a potential downside of -34.72%.
Is BMEA a buy, sell or hold?
- Strong Buy: 4
- Buy: 3
- Hold: 2
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the BMEA price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 7.3 | 277.7% |
| Analysts Target Price | 7.3 | 277.7% |
| ValueRay Target Price | 1.4 | -28% |
Last update: 2025-09-03 04:33
BMEA Fundamental Data Overview
CCE Cash And Equivalents = 56.2m USD (Cash And Short Term Investments, last quarter)
P/B = 4.2182
Beta = -0.16
Revenue TTM = 1.22m USD
EBIT TTM = -114.6m USD
EBITDA TTM = -112.7m USD
Long Term Debt = 28.1m USD (from nonCurrentLiabilitiesTotal, last quarter)
Short Term Debt = 755.0k USD (from shortTermDebt, last quarter)
Debt = 28.8m USD (Calculated: Short Term 755.0k + Long Term 28.1m)
Net Debt = -49.2m USD (from netDebt column, last quarter)
Enterprise Value = 88.7m USD (116.0m + Debt 28.8m - CCE 56.2m)
Interest Coverage Ratio = unknown (Ebit TTM -114.6m / Interest Expense TTM 0.0)
FCF Yield = -135.6% (FCF TTM -120.3m / Enterprise Value 88.7m)
FCF Margin = -9857 % (FCF TTM -120.3m / Revenue TTM 1.22m)
Net Margin = -9188 % (Net Income TTM -112.1m / Revenue TTM 1.22m)
Gross Margin = 26.23% ((Revenue TTM 1.22m - Cost of Revenue TTM 900.0k) / Revenue TTM)
Tobins Q-Ratio = -0.20 (set to none) (Enterprise Value 88.7m / Book Value Of Equity -437.2m)
Interest Expense / Debt = 3.40% (Interest Expense 980.0k / Debt 28.8m)
Taxrate = 21.0% (US default)
NOPAT = -114.6m (EBIT -114.6m, no tax applied on loss)
Current Ratio = 3.68 (Total Current Assets 64.7m / Total Current Liabilities 17.6m)
Debt / Equity = 1.05 (Debt 28.8m / last Quarter total Stockholder Equity 27.5m)
Debt / EBITDA = -0.26 (Net Debt -49.2m / EBITDA -112.7m)
Debt / FCF = -0.24 (Debt 28.8m / FCF TTM -120.3m)
Total Stockholder Equity = 45.9m (last 4 quarters mean)
RoA = -153.2% (set to none)
RoE = -244.0% (Net Income TTM -112.1m / Total Stockholder Equity 45.9m)
RoCE = -154.7% (set to none) (Ebit -114.6m / (Equity 45.9m + L.T.Debt 28.1m))
RoIC = -249.3% (set to none) (NOPAT -114.6m / Invested Capital 45.9m)
WACC = 7.62% (E(116.0m)/V(144.9m) * Re(8.85%)) + (D(28.8m)/V(144.9m) * Rd(3.40%) * (1-Tc(0.21)))
Shares Correlation 3-Years: 100.00 | Cagr: 3.01%
Discount Rate = 8.85% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow -120.3m)
Revenue Correlation: 7.78 | Revenue CAGR: 0.0%
Rev Growth-of-Growth: -1335
EPS Correlation: 20.17 | EPS CAGR: 0.0%
EPS Growth-of-Growth: 40.89
Additional Sources for BMEA Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle